Ikena Oncology Overview

  • Founded
  • 2014
Founded
  • Status
  • Public
  • Employees
  • 33
Employees
  • Stock Symbol
  • IKNA
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $10.80
  • (As of Wednesday Closing)

Ikena Oncology General Information

Description

Ikena Oncology Inc is an oncology company. It is focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. The company is advancing five clinical, preclinical and discovery programs: IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme Kynase; discovery-stage molecules targeting the Hippo signaling pathway; and a discovery-stage program against an undisclosed target.

Contact Information

Formerly Known As
Kyn Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Primary Office
  • 645 Summer Street
  • Suite 101
  • Boston, MA 02210
  • United States
+1 (857) 000-0000

Ikena Oncology Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ikena Oncology Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$10.80 $11.18 $10.33 - $37.61 $470M 35.9M 162K -$5.18

Ikena Oncology Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 1,020,784
Revenue 9,441 9,194 13,753
EBITDA (46,712) (43,956) (16,574)
Net Income (47,027) (44,256) (16,817)
Total Assets 293,662 168,404 85,974
Total Debt 7,637 186 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ikena Oncology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ikena Oncology‘s full profile, request access.

Request a free trial

Ikena Oncology Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Ikena Oncology‘s full profile, request access.

Request a free trial

Ikena Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Ikena Oncology Inc is an oncology company. It is focused on developing novel cancer therapies targeting key signaling pa
Drug Discovery
Boston, MA
33 As of 2021
00000
0000 0000-00-00
00000000 00000

00000000

ommodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fu
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000

00000000

nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
0000000000000
Newtown, PA
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ikena Oncology Competitors (46)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000000 000000000 Formerly VC-backed Newtown, PA 00 00000 00000000 00000
0000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
00000000 000000000 Formerly PE-Backed Cambridge, MA 00 00000 00000000 00000
0000 00000000 Formerly VC-backed San Diego, CA 00 00000 00000000 00000
You’re viewing 5 of 46 competitors. Get the full list »

Ikena Oncology Executive Team (10)

Name Title Board Seat Contact Info
Mark Manfredi Ph.D Founding Member, President, Chief Executive Officer & Board Member
Douglas Carlson Chief Accounting Officer, Accounting & Chief Operating Officer, Operations
Jeffrey Ecsedy Chief Scientific Officer
Maude Tessier Ph.D Executive
Alfredo Castro Ph.D Senior Vice President of Chemistry and Preclinical Development
You’re viewing 5 of 10 executive team members. Get the full list »

Ikena Oncology Board Members (10)

Name Representing Role Since
Atsushi Nagahisa Self Board Member 000 0000
David Bonita MD OrbiMed Board Member 000 0000
George Georgiou Ph.D Self Founder, Board Member & Scientific Advisor 000 0000
Iain Dukes Ph.D OrbiMed Board Member 000 0000
Jean-Francois Formela MD Atlas Venture Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Ikena Oncology Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ikena Oncology Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ikena Oncology‘s full profile, request access.

Request a free trial

Ikena Oncology Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 000000000 01-Oct-2020 000000000000000000 000.00 Other Pharmaceuticals and Biotechnology
Arrys Therapeutics 01-Dec-2018 Merger/Acquisition Drug Discovery
To view Ikena Oncology’s complete acquisitions history, request access »

Ikena Oncology Subsidiaries (1)

Company Name Industry Location Founded
0000000 000000000 Other Pharmaceuticals and Biotechnology Cambridge, MA 0000
To view Ikena Oncology’s complete subsidiaries history, request access »